Results 1 to 10 of about 50,637 (182)

How glucagon-like peptide 1 receptor agonists work [PDF]

Endocrine Connections, 2021
In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show ...
Christine Rode Andreasen, Andreas Andersen, Filip Krag Knop, Tina Vilsbøll   +3 more
doaj   +5 more sources

Glucagon-like peptide-1 receptor agonists in orthopaedics [PDF]

SICOT-J
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) help people control blood glucose and lose weight. They may also help with bone metabolism, healing fractures, keeping joints healthy, and recovering after surgery.
Mavrogenis Andreas F., Altsitzioglou Pavlos, Pililis Sotirios, Anastasilakis Athanasios D., Tournis Symeon, Makras Polyzois, Saranteas Theodosis, Lustig Sebastien   +7 more
doaj   +2 more sources

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists [PDF]

Endocrinology and Metabolism, 2016
Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family, and GLP-1 receptor agonists (RAs) have been introduced as a new class of antidiabetic medications in the past decade.
Yu Mi Kang, Chang Hee Jung
doaj   +3 more sources

Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Arrhythmias [PDF]

Journal of Arrhythmia
Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially designed to treat diabetes mellitus (DM), have demonstrated the potential to mitigate obesity‐related cardiovascular risks.
Vikash Jaiswal, Muhammad Hanif, Aman Goyal, Juveriya Yasmeen, Vamsi Garimella, Yusra Mashkoor, Roopeessh Vempati, Novonil Deb, Yusra Minahil Nasir, Kripa Rajak, Abhigan Babu Shrestha, Jishanth Mattumpuram, Andrew Weinberg   +12 more
doaj   +2 more sources

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes

Journal of Diabetes
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). Most supportive evidence of a kidney‐protective effect of
Richard J. MacIsaac, Philippa Trevella, Elif I. Ekinci   +2 more
doaj   +3 more sources

Glucagon-like peptide-1 receptor agonists in neoplastic diseases

Frontiers in Endocrinology
Glucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing weight, and lowering blood lipids.
Lisan Ji, Xianzhen He, Xinwen Min, Handong Yang, Wenwen Wu, Hao Xu, Jun Chen, Jun Chen, Aihua Mei   +8 more
doaj   +3 more sources

Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea [PDF]

Obesity Science & Practice
Background and Aim Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists are well‐established therapies for obesity and type 2 diabetes mellitus (T2DM). Emerging evidence also suggests their potential role in managing obstructive sleep apnea (OSA).
Bei‐Bei Qian, Yu‐Jie Huang, Cai‐Feng Yan, Shang‐Yong Feng, Dun‐Min She   +4 more
doaj   +2 more sources

Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis [PDF]

ACR Open Rheumatology
Objective Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) are approved for weight loss, diabetes, and cardiovascular risk reduction. Despite widespread use, GLP‐1RAs have not been well studied in patients with rheumatoid arthritis (RA).
David A. Kellner, Elizabeth Dente, Vincent Tran, Travis Welsh, Victor Tran, Angshuman Saha, Joshua F. Baker, David A. Elashoff, Veena K. Ranganath   +8 more
doaj   +2 more sources

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis

Frontiers in Endocrinology, 2021
ObjectiveNon-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus. Studies on glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease have reported promising results. Despite
Chloe Wong, Ming Hui Lee, Clyve Yu Leon Yaow, Yip Han Chin, Xin Lei Goh, Cheng Han Ng, Amanda Yuan Ling Lim, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Mark Dhinesh Muthiah, Mark Dhinesh Muthiah, Chin Meng Khoo, Chin Meng Khoo   +12 more
doaj   +1 more source

History of glucagon-like peptide-1 receptor agonists

Pharmacological Research
Radwan Darwish, Ghena Abu-Sharia, Alexandra E. Butler   +2 more
doaj   +2 more sources